IT1308613B1 - Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. - Google Patents

Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.

Info

Publication number
IT1308613B1
IT1308613B1 IT1999MI000313A ITMI990313A IT1308613B1 IT 1308613 B1 IT1308613 B1 IT 1308613B1 IT 1999MI000313 A IT1999MI000313 A IT 1999MI000313A IT MI990313 A ITMI990313 A IT MI990313A IT 1308613 B1 IT1308613 B1 IT 1308613B1
Authority
IT
Italy
Prior art keywords
fatty acids
essential fatty
dha
epa
patient
Prior art date
Application number
IT1999MI000313A
Other languages
English (en)
Inventor
Franco Pamparana
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11381919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1308613(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Priority to IT1999MI000313A priority Critical patent/IT1308613B1/it
Priority to DK00907510T priority patent/DK1152755T3/da
Priority to PT00907510T priority patent/PT1152755E/pt
Priority to EP00907510A priority patent/EP1152755B1/en
Priority to AU29075/00A priority patent/AU775078B2/en
Priority to ES00907510T priority patent/ES2174814T3/es
Priority to SK1080-2001A priority patent/SK286523B6/sk
Priority to DE60000133.4T priority patent/DE60000133C5/de
Priority to KR1020077019755A priority patent/KR20070098954A/ko
Priority to IL14437700A priority patent/IL144377A0/xx
Priority to PCT/EP2000/000957 priority patent/WO2000048592A1/en
Priority to IDW00200101999A priority patent/ID30205A/id
Priority to CA002362271A priority patent/CA2362271C/en
Priority to HK02106382.1A priority patent/HK1044720B/zh
Priority to AT00907510T priority patent/ATE216230T1/de
Priority to KR1020017010387A priority patent/KR100823051B1/ko
Priority to BR0008153-1A priority patent/BR0008153A/pt
Priority to NZ513093A priority patent/NZ513093A/xx
Priority to HU0200111A priority patent/HUP0200111A3/hu
Priority to EP20020076100 priority patent/EP1247523A1/en
Priority to EA200100895A priority patent/EA004312B1/ru
Priority to PL350851A priority patent/PL209078B1/pl
Priority to US09/869,333 priority patent/US7462643B1/en
Priority to CNB008050732A priority patent/CN1230159C/zh
Priority to CZ20012947A priority patent/CZ301307B6/cs
Priority to JP2000599384A priority patent/JP5441287B2/ja
Publication of ITMI990313A1 publication Critical patent/ITMI990313A1/it
Priority to IL144377A priority patent/IL144377A/en
Priority to ZA200106029A priority patent/ZA200106029B/en
Priority to NO20013938A priority patent/NO328797B1/no
Publication of IT1308613B1 publication Critical patent/IT1308613B1/it
Application granted granted Critical
Priority to US12/192,627 priority patent/US20090018193A1/en
Priority to JP2010014742A priority patent/JP2010116414A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT1999MI000313A 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. IT1308613B1 (it)

Priority Applications (31)

Application Number Priority Date Filing Date Title
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
BR0008153-1A BR0008153A (pt) 1999-02-17 2000-02-07 Uso de ácidos graxos essenciais na prevenção de eventos cardiovasculares
NZ513093A NZ513093A (en) 1999-02-17 2000-02-07 Use of the essential fatty acids eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in the prevention of cardiovascular events
EP00907510A EP1152755B1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
AU29075/00A AU775078B2 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
ES00907510T ES2174814T3 (es) 1999-02-17 2000-02-07 Acidos grasos esenciales destinados en la prevencion de accidentes cardio-vasculares.
SK1080-2001A SK286523B6 (sk) 1999-02-17 2000-02-07 Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu
DE60000133.4T DE60000133C5 (de) 1999-02-17 2000-02-07 Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
KR1020077019755A KR20070098954A (ko) 1999-02-17 2000-02-07 심혈관 사고 예방용 필수 지방산을 포함하는 약제학적조성물
IL14437700A IL144377A0 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
PCT/EP2000/000957 WO2000048592A1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
IDW00200101999A ID30205A (id) 1999-02-17 2000-02-07 Asam-asam lemak esensial dalam pencegahan kejadian-kejadian kardiovaskular
CA002362271A CA2362271C (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
HK02106382.1A HK1044720B (zh) 1999-02-17 2000-02-07 必需脂肪酸在预防心血管疾病中的应用
AT00907510T ATE216230T1 (de) 1999-02-17 2000-02-07 Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
KR1020017010387A KR100823051B1 (ko) 1999-02-17 2000-02-07 심혈관 사고 예방용 필수 지방산을 포함하는 약제학적 조성물
DK00907510T DK1152755T3 (da) 1999-02-17 2000-02-07 Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde
EP20020076100 EP1247523A1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
PT00907510T PT1152755E (pt) 1999-02-17 2000-02-07 Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares
HU0200111A HUP0200111A3 (en) 1999-02-17 2000-02-07 Use of essential fatty acids for preparation of pharmaceutical composition available in the prevention of cardiovascular events
EA200100895A EA004312B1 (ru) 1999-02-17 2000-02-07 Применение эйкозапентаеновой и/или докозагексаеновой жирных кислот и/или их этиловых эфиров для приготовления лекарственного средства для снижения уровня смертности пациентов, перенесших инфаркт миокарда
PL350851A PL209078B1 (pl) 1999-02-17 2000-02-07 Zastosowanie niezbędnych kwasów tłuszczowych zawierających mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego do wytwarzania leku
US09/869,333 US7462643B1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events
CNB008050732A CN1230159C (zh) 1999-02-17 2000-02-07 必需脂肪酸在预防心血管疾病中的应用
CZ20012947A CZ301307B6 (cs) 1999-02-17 2000-02-07 Použití esenciálních mastných kyselin pro prevenci kardiovaskulárních príhod
JP2000599384A JP5441287B2 (ja) 1999-02-17 2000-02-07 心血管事象を予防するための必須脂肪酸
IL144377A IL144377A (en) 1999-02-17 2001-07-17 Fatty acids are essential for use in preventing events in the heart system
ZA200106029A ZA200106029B (en) 1999-02-17 2001-07-23 Essential fatty acids in the prevention of cardiovascular events.
NO20013938A NO328797B1 (no) 1999-02-17 2001-08-14 Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt.
US12/192,627 US20090018193A1 (en) 1999-02-17 2008-08-15 Essential fatty acids in the prevention of cardiovascular events
JP2010014742A JP2010116414A (ja) 1999-02-17 2010-01-07 心血管事象を予防するための必須脂肪酸

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.

Publications (2)

Publication Number Publication Date
ITMI990313A1 ITMI990313A1 (it) 2000-08-17
IT1308613B1 true IT1308613B1 (it) 2002-01-09

Family

ID=11381919

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.

Country Status (26)

Country Link
US (2) US7462643B1 (it)
EP (2) EP1152755B1 (it)
JP (2) JP5441287B2 (it)
KR (2) KR100823051B1 (it)
CN (1) CN1230159C (it)
AT (1) ATE216230T1 (it)
AU (1) AU775078B2 (it)
BR (1) BR0008153A (it)
CA (1) CA2362271C (it)
CZ (1) CZ301307B6 (it)
DE (1) DE60000133C5 (it)
DK (1) DK1152755T3 (it)
EA (1) EA004312B1 (it)
ES (1) ES2174814T3 (it)
HK (1) HK1044720B (it)
HU (1) HUP0200111A3 (it)
ID (1) ID30205A (it)
IL (2) IL144377A0 (it)
IT (1) IT1308613B1 (it)
NO (1) NO328797B1 (it)
NZ (1) NZ513093A (it)
PL (1) PL209078B1 (it)
PT (1) PT1152755E (it)
SK (1) SK286523B6 (it)
WO (1) WO2000048592A1 (it)
ZA (1) ZA200106029B (it)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
BR0309740A (pt) 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
MX291518B (es) * 2004-04-16 2011-10-31 Solvay Pharm Gmbh Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria.
CA2601985C (en) 2005-03-11 2013-07-16 Recon Oil Industries Private Limited A synergistically heat stable oil media having eicosa pentaenoic acid (epa) and do-cosa hexaenoic acid (dha)
KR101465715B1 (ko) * 2005-07-08 2014-11-27 모치다 세이야쿠 가부시키가이샤 심혈관 이벤트 발병 예방용 조성물
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
EP3263101A1 (en) 2005-12-21 2018-01-03 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
EP2526937A1 (en) 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
EP2777701A1 (en) * 2006-05-31 2014-09-17 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
EP2323647B1 (en) * 2008-08-07 2014-09-10 SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. Long-term treatment of symptomatic heart failure
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
EP2475309A4 (en) * 2009-09-08 2015-07-29 Atrium Medical Corp HERNIAPFLASTER
CA2873141C (en) 2009-12-30 2018-05-29 Adam Kelliher Simulated moving bed chromatographic separation process
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
KR101681907B1 (ko) * 2012-02-27 2016-12-12 주식회사 케어사이드 혈액 순환 촉진 및 피부 질환 개선용 조성물
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
EP2830602B1 (en) 2012-03-30 2020-10-21 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
WO2014057362A2 (en) * 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP2883860B1 (fr) 2013-12-11 2016-08-24 Novasep Process Procédé chromatographique de production d'acides gras polyinsaturés
JP6303017B2 (ja) 2014-01-07 2018-03-28 ノヴァセプ プロセスＮｏｖａｓｅｐ Ｐｒｏｃｅｓｓ 芳香族アミノ酸を精製する方法
PL237374B1 (pl) * 2017-11-10 2021-04-06 Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
NO157302C (no) 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
JP2893866B2 (ja) 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5324323A (en) 1992-09-09 1994-06-28 Telectronics Pacing Systems, Inc. Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
WO1994013642A1 (de) 1992-12-11 1994-06-23 Ciba-Geigy Ag Substituierte benzazepinone
CN1082909A (zh) * 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH07118229A (ja) 1993-10-19 1995-05-09 Fujisawa Pharmaceut Co Ltd 尿素誘導体およびその製造法
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) 1994-06-30 1996-01-16 Fujirebio Inc 虚血性心疾患治療剤
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
WO1998010085A2 (en) 1996-09-05 1998-03-12 The Regents Of The University Of California Gene therapy for congestive heart failure
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6313167B1 (en) 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1130027A1 (de) 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
PL350851A1 (en) 2003-02-10
EA200100895A1 (ru) 2002-02-28
CN1230159C (zh) 2005-12-07
ITMI990313A1 (it) 2000-08-17
EP1152755B1 (en) 2002-04-17
ZA200106029B (en) 2002-09-25
HUP0200111A2 (hu) 2002-05-29
AU2907500A (en) 2000-09-04
KR20070098954A (ko) 2007-10-05
NZ513093A (en) 2003-02-28
EP1152755A1 (en) 2001-11-14
JP5441287B2 (ja) 2014-03-12
DE60000133C5 (de) 2014-02-27
NO20013938L (no) 2001-08-14
AU775078B2 (en) 2004-07-15
US20090018193A1 (en) 2009-01-15
WO2000048592A1 (en) 2000-08-24
DE60000133D1 (de) 2002-05-23
KR20010102183A (ko) 2001-11-15
ID30205A (id) 2001-11-15
DK1152755T3 (da) 2002-07-22
HK1044720B (zh) 2006-08-18
JP2010116414A (ja) 2010-05-27
EA004312B1 (ru) 2004-02-26
SK286523B6 (sk) 2008-12-05
DE60000133T2 (de) 2002-11-21
IL144377A (en) 2006-12-10
CA2362271A1 (en) 2000-08-24
PL209078B1 (pl) 2011-07-29
HK1044720A1 (en) 2002-11-01
ATE216230T1 (de) 2002-05-15
NO328797B1 (no) 2010-05-18
JP2002537252A (ja) 2002-11-05
CA2362271C (en) 2008-07-15
BR0008153A (pt) 2001-11-06
EP1247523A1 (en) 2002-10-09
CZ301307B6 (cs) 2010-01-06
NO20013938D0 (no) 2001-08-14
CZ20012947A3 (cs) 2002-04-17
KR100823051B1 (ko) 2008-04-18
HUP0200111A3 (en) 2003-03-28
PT1152755E (pt) 2002-09-30
IL144377A0 (en) 2002-05-23
ES2174814T3 (es) 2002-11-16
CN1343120A (zh) 2002-04-03
SK10802001A3 (sk) 2001-12-03
US7462643B1 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
ID30205A (id) Asam-asam lemak esensial dalam pencegahan kejadian-kejadian kardiovaskular
US5198468A (en) Essential fatty acid composition
PT1310249E (pt) Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves
YU59303A (sh) Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca
DE69935995D1 (de) Polyungesättigen fettsäuren nährungsergänzung
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
CA2043137A1 (en) Essential fatty acid treatment
BRPI0009373B8 (pt) composições farmacêuticas orais contendo triglicerídeos de cadeia longa e tensoativos lipofílicos
FI963867A0 (fi) Rasvahappoestereiden käyttö bioadhesiivisina aineina
ES2117390T3 (es) Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.
GB0016045D0 (en) Therapeutic combinations of fatty acids
DK0623019T3 (da) Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
CA2302641A1 (en) Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation
CA2411568A1 (en) Compositions for the therapy of dementias
JPH04273817A (ja) 低密度リポ蛋白受容体活性化剤
JPH08310948A (ja) 抗脱毛症剤
TH15808A (th) ไทรกลีเซอไรด์ กรรมวิธีสำหรับการผลิต c-ซับสทิทิว?เทด?ไดเอธิลีนไทรแอมีน
RU97102697A (ru) Применение дгк в качестве фармацевтической композиции